Cardinal Health heads into the first full week of May under pressure, having shed 4.2% over the past week to close at $197, while the Street digests a mixed earnings signal and a wave of freshly cut price targets.
The earnings read tells the story of a split tape. The Q3 fiscal-year result released May 1 delivered a modest next-day gain of 2.2%, a reasonable outcome given the stock had fallen roughly 8% over the prior month into the print. Yet the reaction was muted relative to the scale of analyst movement that followed. JP Morgan's Lisa Gill — reporting within 48 hours of the release — cut her target by $28 to $215, one of the sharper single-session adjustments seen from a major firm this cycle, while maintaining Neutral. Wells Fargo trimmed from $256 to $245, holding Overweight. Citi shaved a few points off its Buy-rated target to $245. The outlier was TD Cowen, which lifted its target from $251 to $255 on a Buy. The net message from the Street is cautious confidence: most analysts still see significant upside from current levels, but the number they put on it is moving lower. The mean price target across the coverage now stands at $245 — a 24% gap over the $197 close that implies the Street thinks the stock is clearly undervalued, even after the trimming.
Short positioning on Cardinal Health is modest and does not tell a particularly charged story. SI is running at roughly 2.5% of the free float, barely changed over the week at around 5.9 million shares. Borrow conditions are as relaxed as they come — cost to borrow is just 0.38% annualised, and availability is wide. The ORTEX short score sits at 33.8, well below any level that would flag elevated short pressure. Options are similarly calm. The put/call ratio at 0.72 is actually running below its 20-day average of 0.76, placing it nearly a full standard deviation on the call-favoured side of normal. None of this points to a market leaning hard against the company; the weekly price weakness is not being reinforced by an aggressive short build.
The fundamental backdrop offers genuine support to the bull case. Cardinal Health generated roughly $3.6 billion in operating cash flow on revenues of $256 billion, a reminder that pharmaceutical distribution is a volume game with thin margins but enormous scale. The EV/EBITDA multiple has drifted down to around 12.6x, compressing roughly 0.2x over 30 days as the stock has weakened. The forward earnings yield has climbed to 5.7%, its highest in recent months, reflecting the repricing. On ORTEX factor scores, the company ranks in the 94th percentile for forward EPS growth and 86th percentile for 30-day EPS momentum — signals that estimate revisions have been running in a positive direction even as the stock retreats. The EPS surprise rank at the 33rd percentile is softer, consistent with a company whose beats have been thin rather than spectacular. William Blair initiated coverage on Outperform at the end of April, the most recent new voice to join the bullish camp.
Peer performance adds useful context. Closest correlate MCK fell 4.1% on the week, almost in lockstep with Cardinal Health, while COR — Cencora — held up meaningfully better, off just 2%. COR also missed Q2 earnings and revenue estimates this week but managed to raise its FY26 EPS outlook, which helped the stock absorb the miss. The shared weakness across drug distributors suggests the move in Cardinal Health is more sector-level caution than company-specific alarm.
On the institutional side, the large passive holders — Vanguard at 13.4% and BlackRock at 12.2% — both reported modest increases in their latest filings, consistent with index drift rather than active conviction. No notable active-manager reduction is visible in the top-holder list. Insider activity is stale relative to today's price, with the most recent transactions from late February at prices in the $220s, all of which were sales. The net 90-day insider balance is slightly positive in share terms, but the sales pattern at prices well above the current level is a data point worth noting as context. Cardinal Health also declared a quarterly dividend of $0.52 per share this week, which at the current price implies a forward yield close to 1.1%, the factor score for dividend quality ranking at the 91st percentile.
The next earnings event is not until mid-August, so the near-term focus is on whether guidance commentary from this week's print settles the analyst community or triggers further target compression. The gap between the mean Street target of $245 and the $197 handle is wide enough that further cuts without a corresponding re-rating of the stock could quietly close the implied upside and shift the balance of analyst opinion.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
